# Ilaria

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10051605/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 22 papers | 678 citations | 759233 12 h-index | 794594 19 g-index |
| 22 all docs | 22 docs citations | 22 times ranked | 1367 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer, 2022, 162, 221-236. | 2.8 | 22 |
| 2 | Theragnostic in neuroendocrine tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, . | 0.7 | 2 |
| 3 | 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 152-160. | 6.4 | 20 |
| 4 | Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3260-3267. | 6.4 | 29 |
| 5 | Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2021, 14, 476. | 3.8 | 16 |
| 6 | 606P Novel miRNA-based assay for GEP-NENs management. Annals of Oncology, 2020, 31, S505. | 1.2 | 0 |
| 7 | Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Managementâ€"An Updated Review. Frontiers in Oncology, 2020, 10, 831. | 2.8 | 27 |
| 8 | A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. Journal of Visualized Experiments, 2020, , . | 0.3 | 8 |
| 9 | Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346. | 1.1 | 8 |
| 10 | Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. OncoTargets and Therapy, 2017, Volume 10, 551-557. | 2.0 | 37 |
| 11 | Reply to H.J.A. Adams et al and E. Laffon et al. Journal of Clinical Oncology, 2017, 35, 920-923. | 1.6 | 3 |
| 12 | Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 2016, 41, e87-e92. | 1.3 | 32 |
| 13 | Baseline Metabolic Tumor Volume Predicts Outcome in Highâ€"Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. Journal of Clinical Oncology, 2016, 34, 3618-3626. | 1.6 | 231 |
| 14 | Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. Blood, 2015, 126, 3919-3919. | 1.4 | 0 |
| 15 | Usefulness of 64Cu-ATSM in Head and Neck Cancer. Clinical Nuclear Medicine, 2014, 39, e59-e63. | 1.3 | 36 |
| 16 | FDG and other radiopharmaceuticals in the evaluation of liver lesions. Clinical and Translational Imaging, 2014, 2, 115-127. | 2.1 | 2 |
| 17 | Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study. Current Radiopharmaceuticals, 2014, 7, 107-114. | 0.8 | 3 |
| 18 | PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84. | 1.0 | 109 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | 811 poster 64CU-ATSM PET/CT AND 18F-FDG-PET/CT IN THE STAGING AND TARGET VOLUME DELINEATION FOR HEAD AND NECK CANCER (H&N).. Radiotherapy and Oncology, 2011, 99, S316-S317. | 0.6 | 0 |
| 20 | I-123 MIBG Scintigraphy and 68Ga-DOTANOC PET/CT Negative But F-18 DOPA PET/CT Positive Pheochromocytoma. Clinical Nuclear Medicine, 2011, 36, 124-126. | 1.3 | 9 |
| 21 | Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 797-804. | 2.6 | 40 |
| 22 | Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. European Journal of Endocrinology, 2008, 159, 347-353. | 3.7 | 44 |